An­oth­er NASH de­lay for In­ter­cept frus­trates in­vestors, shares wilt

A pre­vi­ous FDA ad­vi­so­ry com­mit­tee de­lay for In­ter­cept’s NASH drug may have damp­ened spir­its, but in­vestors perked up af­ter French ri­val Gen­fit re­cent­ly failed to best a place­bo with its of­fer­ing in a keen­ly an­tic­i­pat­ed piv­otal study. In yet an­oth­er twist on Fri­day, the New York drug­mak­er said the FDA is post­pon­ing its ad­com again to ac­com­mo­date the re­view of ad­di­tion­al da­ta it has asked the com­pa­ny to fur­nish.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER